Hledání článků
Filtry
Kramers BJ, Koorevaar IW, van Gastel MDA, et al. Effect of hydrochlorothiazide and metformin on aquaresis and nephroprotection by a vasopressin V2 receptor antagonist in ADPKD. Clin J Am Soc Nephrol 2022;17:507–517.
Dai L, Massy ZA, Stenvinkel P, et al.; EQUAL study investigators. The association between TMAO, CMPF and clinical outcomes in advanced chronic kidney disease; results from the European QUALity (EQUAL) Study. Am J Clin Nutr 2022 Sep 27:nqac278. doi: 10.1093/ajcn/nqac278. Online ahead of print.
EMPA‑Kidney Collaborative Group, Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2022 Nov 4, doi: 10.1056/NEJMoa2204233.
Ponte C, Grayson PC, Robson JC, et al; DCVAS Study Group. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis 2022;81:1647–1653. Arthritis Rheumatol 2022 Nov 8. doi: 10.1002/art.42325. Epub ahead of print.
Grayson PC, Ponte C, Suppiah R, et al; DCVAS Study Group. 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis.
Ann Rheum Dis 2022;81:1654–1660. Arthritis Rheumatol 2022 Nov 8. doi: 10.1002/art.42324. Epub ahead of print. PMID: 36349501.
Rossing P, Caramori ML, Chan JCN, et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int 2022;102:990–999.
Miano TA, Hennessy S, Yang W, et al. Association of vancomycin plus piperacillin–tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study. Intensive Care Med 2022;48:1144–1155.
Hummel A, Oniszczuk J, Kervella D, et al. Idiopathic nephrotic syndrome relapse following COVID‑19 vaccination: a series of 25 cases. Clin Kidney J 2022;15:1574–1582.
Shlipak MG, Shashadri A, Hsu FC, et al. Effect of structured, moderate exercise on kidney function decline in sedentary older adults: an ancillary analysis of the LIFE randomized clinical trial. JAMA Intern Med 2022;182:650–659.
Senum SR, Ying M, Benson KA, Joli G, Genomics England Research Consortium, the HALT PKD, CRISP, DIPAK, ADPKD Modifier, and TAME PKD studies, Harris PC. Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney‑spectrum phenotype. Am J Hum Genet 2022;109:136–156.